Procedural and follow-up outcomes among patients undergoing successful recanalisation of coronary chronic total occlusions using biolimus drug-eluting stents

详细信息    查看全文

• 作者：S. Saraf (1)
  J. Cockburn (1)
  I. Ferreira (1)
  S. Hopkins (1)
  D. Hildick-Smith (1)
  
• 关键词：Biolimus A9 ; Chronic total occlusion ; Coronary angioplasty
• 刊名：Cardiovascular Intervention and Therapeutics
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：29
• 期：3
• 页码：216-220
• 全文大小：170 KB
• 参考文献：1. Windecker S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. The Lancet. 2008;372:1163-3. CrossRef
  2. Barlis P, Regar E, Serruys PW, Dimopoulos K, Van der Giessen WJ, Van Geuns RJ, Ferrante G, Wandel SM, Windecker S, Van Es GA, Eerdmans P, Juni P, Di Mario C. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J. 2010;2:165-6. CrossRef
  3. Wykrzykowska J, Serruys P, Vries TD, et al. Three year outcomes of chronic total occlusion treatment with biolimus eluting biodegradable polymer stent versus sirolimus eluting permanent polymer stent in the LEADERS all-comers trial. J Am Coll Cardiol. 2011;58:B75-.
  4. Grube E, Buellesfeld L. BioMatrix biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices. 2006;3:731-1. CrossRef
  5. Danzi G, Chevalier B, Urban B, Fath-Ordoubad F, Carrie D, Wiemer M, Serra A, Wijns W, Kala P, Stabile A, Ruigomez G, Laanmets P, Strupp G, West N, Paunovic D, on behalf of NOBORI 2 Investigators. Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. EuroIntervention. 2012;8:109-6. CrossRef
  6. Sirnes P, Golf S, Myreng Y, Molstad P, Emanuelsson H, Albertsson P, Brekke M, Mangschau A, Endresen K, Kjekshus J. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol. 1996;28:1444-1. CrossRef
  7. Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, Vassanelli C, Campolo L, Martuscelli E, Tommasini G. Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Ste nelle Occlusioni Coronariche. J Am Coll Cardiol. 1998;32:90-. CrossRef
  8. Hoher M, Wohrle J, Grebe O, Kochs M, Osterhues HH, Hombach V, Buchwald A. A randomized trial of elective stenting after balloon recanalization of chronic total occlusions. J Am Coll Cardiol. 1999;34:722-. CrossRef
  9. Lotan C, Rozenman Y, Hendler A, Turgeman Y, Ayzenberg O, Beyar R, Krakover R, Rosenfeld T, Gotsman M. Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional Cardiology. Eur Heart J. 2000;21:1960-. CrossRef
  10. Rubartelli P, Verna E, Niccoli L, Giachero C, Zimarino M, Bernardi G, Vassanelli C, Campolo L, Martuscelli E. Coronary stent implantation is superior to balloon angioplasty for chronic coronary occlusions: six year clinical follow-up of the GISSOC trial. J Am Coll Cardiol. 2003;41:1488-2. CrossRef
  11. Tamai H, Berger PB, Tsuchikane E, Suzuki T, Nishikawa H, Aizawa T, Fujii K, Nozaki Y, Kyo E, Kobayashi T, Reiber J, Van Weert AW. Frequency and time course of reocclusion and restenosis in coronary artery occlusions after balloon angioplasty versus Wiktor stent implantation: results from the Mayo-Japan Investigation for Chronic Total Occlusion (MAJIC) trial. Am Heart J. 2004;147:E9. CrossRef
  12. Sievert H, Rohde S, Utech A, Schulze R, Scherer D, Merle H, Ensslen R, Schrader R, Spies H, Fach A. Stent or angioplasty after recanalization of chronic coronary occlusions? (The SARECCO Trial). Am J Cardiol. 1999;84:386-0. CrossRef
  13. Buller C, Dzavik V, Carere RG, Mancini G, Barbeau G, Lazzam C, Anderson TJ, Knudtson M, Marquis J, Suzuki T, Cohen E, Fox R, Teo K. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation. 1999;100:236-2. CrossRef
  14. Moses J, Leon M, Popma J, Fitzgerald P, Holmes D, O’Shaughnessy C, Caputo R, Kereiakes D, Williams D, Teirstein P, Jaeger J, Kuntz R. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-3. CrossRef
  15. Huang PH, Yeung M, Cox DA, Bowman TS, Starzyk RM, Dawkins KD. Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS?ARRIVE program. J Interv Cardiol. 2011;24:232-0. CrossRef
  16. Ge L, Lakovou L, Cosgrave J, Chieffo A, Montorfano M, Michev L, Airoldi F, Carlino M, Melzi G, Sangiorgi G, Corvaja N, Colombo A. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J. 2005;26:1056-2. CrossRef
  17. Galassi AR, Tomasello SD, Costanzo L, Campisano MB, Barrano G, Tamburino C. Long-term clinical and angiographic results of Sirolimus-Eluting Stent in Complex Coronary Chronic Total Occlusion Revascularization: the SECTOR registry. J Interv Cardiol. 2011;24:426-6. CrossRef
  18. Park HJ, Kim HY, Lee JM, Choi YS, Park CS, Kim DB, Her SH, Koh YS, Park MW, Kwon BJ, Kim PJ, Chang K, Chung WS, Seung KB. Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion–CAtholic Total Occlusion Study (CATOS) trial. Circ J. 2012;76:868-5. CrossRef
  19. W?hrle J, Rottbauer W, Imhof A. Everolimus-eluting stents for treatment of chronic total coronary occlusions. Clin Res Cardiol. 2012;101:23-. CrossRef
  20. http://www.tctmd.com/show.aspx?id=112366.
  21. Chieffo A, Bonizzoni E, Orlic D, Stankovic G, Rogacka R, Airoldi R, Airoldi F, Mikhail GW, Montorfano M, Michev I, Carlino M, Colombo A. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation. 2004;109:2732-. CrossRef
  22. Suttorp M, Laarman G, Rahel B, Kelder J, Bosschaert M, Kiemeneij F, Ten Berg J, Bal E, Rensing B, Eefting F, Mast E. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006;114:921-. CrossRef
  23. Sarno G, Lagerqvist B, Fr?bert O, Nilsson J, Olivecrona G, Omerovic E, Saleh N, Dimitris Venetzanos D, James S. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation-drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33:606-3. CrossRef
  
• 作者单位：S. Saraf (1)
  J. Cockburn (1)
  I. Ferreira (1)
  S. Hopkins (1)
  D. Hildick-Smith (1)
  
  1. Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, UK
  
• ISSN：1868-4297

文摘

This study aimed at evaluating the outcome of Biolimus eluting stent (BES) implantation in the treatment of chronic total coronary occlusions (CTO). We identified patients who underwent successful angioplasty for a CTO lesion with ? BES between June 2008 and March 2012. All patients were followed up for major adverse cardiac events (MACE), which comprised death, non-fatal myocardial infarction (MI), cerebrovascular accident, target vessel revascularization (TVR), target lesion revascularization (TLR) and stent thrombosis. 125 patients underwent successful CTO angioplasty with ? Biolimus-eluting stents. Mean age was 63.8?±?12.0?years, and 82.4?% were males. Lesion location was right coronary artery (n?=?80, 64?%), left anterior descending artery (n?=?35, 28?%) and left circumflex artery (n?=?10, 8?%). During follow-up of 579?±?293?days, all cause mortality was n?=?8 (6.4?%) patients, non-fatal MI was n?=?3 (2.4?%), TVR was n?=?3 (2.4?%) and TLR was n?=?1 (0.8?%). Overall MACE was, therefore, n?=?15 (12?%). BES is safe and effective in treatment of CTO lesions, with a low rate of major adverse cardiovascular events during follow-up.